Ethic Inc. Raises Position in DaVita Inc. (NYSE:DVA)

Ethic Inc. lifted its stake in DaVita Inc. (NYSE:DVA) by 116.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,345 shares of the company’s stock after buying an additional 2,340 shares during the period. Ethic Inc.’s holdings in DaVita were worth $650,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Deutsche Bank AG boosted its position in shares of DaVita by 35.2% in the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company’s stock worth $58,687,000 after buying an additional 102,230 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of DaVita in the fourth quarter worth about $106,000. Crestline Management LP lifted its stake in shares of DaVita by 19.1% in the fourth quarter. Crestline Management LP now owns 5,034 shares of the company’s stock worth $753,000 after acquiring an additional 808 shares in the last quarter. BOKF NA lifted its stake in shares of DaVita by 55.2% in the fourth quarter. BOKF NA now owns 8,963 shares of the company’s stock worth $1,375,000 after acquiring an additional 3,188 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of DaVita in the fourth quarter worth about $322,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 2.7%

Shares of NYSE DVA opened at $140.10 on Thursday. The stock’s 50 day moving average price is $145.87 and its two-hundred day moving average price is $153.58. DaVita Inc. has a 52-week low of $131.44 and a 52-week high of $179.60. The stock has a market capitalization of $10.77 billion, a P/E ratio of 13.04, a PEG ratio of 1.07 and a beta of 1.14. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter in the prior year, the firm posted $2.26 earnings per share. DaVita’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.